<DOC>
	<DOCNO>NCT02636101</DOCNO>
	<brief_summary>This study aim describe patient population treat real-life patient ' experience Xamiol®gel long term , 52 week management body psoriasis vulgaris Russia . The result increase knowledge Xamiol®gel enable dermatologist patient optimize use long term management psoriasis .</brief_summary>
	<brief_title>Xamiol®Gel BODY Psoriasis : A One-year Non-interventional Study</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Betamethasone-17,21-dipropionate</mesh_term>
	<mesh_term>Betamethasone benzoate</mesh_term>
	<mesh_term>Betamethasone</mesh_term>
	<mesh_term>Betamethasone Valerate</mesh_term>
	<mesh_term>Betamethasone sodium phosphate</mesh_term>
	<mesh_term>Calcipotriene</mesh_term>
	<criteria>Psoriasis vulgaris body Patients plan receive topical treatment body calcipotriol/betamethasone gel Written inform consent No mild symptom psoriasis vulgaris body study start Any ongoing treatment study start topical steroid , salicylic acid combination Other topical treatment body psoriasis Pregnancy plan pregnancy within treatment period Contraindications accord prescribe information .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>